The research team, led by Egle Milasauskiene of the Laboratory of Behavioral Medicine at the Lithuanian University of Health Sciences, with collaborators including Guy C. Brown of the University of Cambridge, set out to address a persistent gap. Immune dysregulation and gut-derived inflammation have been implicated in a subset of patients with depression for years, yet their diagnostic usefulness across different levels of illness severity, and their sensitivity to psychotropic treatment, remained unclear. To probe these questions, the investigators quantified LPS and four cytokines—TNF-alpha, interleukin-6, interleukin-10, and interferon-gamma—in the circulation of participants, and assessed depression severity using the Montgomery–Åsberg Depression Rating Scale, stratifying patients into mild-to-moderate and severe groups.

The headline result was a clear divergence in inflammatory profiles. Compared with healthy controls, patients with major depressive disorder showed elevated LPS and TNF-alpha and reduced interleukin-10, an anti-inflammatory cytokine, while interleukin-6 and interferon-gamma did not differ between the groups. Crucially, the elevation of LPS was specific to patients with mild-to-moderate depression, whereas TNF-alpha was raised across all severity levels. This pattern suggests that translocation of bacterial products from the gut into the bloodstream may be a feature of earlier or less severe stages of the illness, while a more systemic pro-inflammatory state, driven by TNF-alpha, accompanies greater severity.

From a technical standpoint, the diagnostic potential of these markers was assessed using receiver operating characteristic analysis, which quantifies how well a biomarker or combination of biomarkers separates cases from controls. A combined model incorporating LPS, TNF-alpha, and interleukin-10 achieved the highest diagnostic accuracy for major depressive disorder overall, with an area under the curve of 0.778, and performed even better for mild-to-moderate disease, reaching an AUC of 0.818. For severe depression, TNF-alpha alone was the strongest predictor, with an AUC of 0.677, while LPS alone distinguished mild-to-moderate from severe depression with an AUC of 0.679. These values, while not yet in the range of a standalone clinical test, indicate meaningful discriminatory power for markers that can be measured in a routine blood sample.

Importantly, the associations survived rigorous statistical scrutiny. The researchers adjusted their analyses for age, sex, body mass index, smoking status, and psychotropic medication use, and the links between the biomarkers and depression severity remained significant. This matters because confounders such as smoking and obesity are known to influence inflammatory markers, and because antidepressants and other psychotropic drugs could theoretically alter immune signaling. By demonstrating that the LPS and cytokine patterns hold after adjustment, the study strengthens the case that these molecules reflect genuine disease-related biology rather than artifacts of lifestyle or treatment.

That said, medication was not biologically inert in the data. LPS levels were higher among patients with mild-to-moderate depression who were receiving antidepressant monotherapy, and lower among those on combination therapy, regardless of severity. The authors interpret this cautiously, noting that the cross-sectional design cannot determine whether combination treatment suppresses gut-derived inflammation or whether patients on combination regimens differed in other relevant ways. Even so, the observation raises the intriguing possibility that certain pharmacological strategies may dampen bacterial translocation from the gut, and that treatment effects on inflammatory biomarkers could one day inform the choice of therapeutic regimen.

The conceptual payoff of the study lies in its subdivision of depression. Mild-to-moderate major depressive disorder, in this framework, is associated with elevated LPS, reflecting gut-derived inflammation and potentially constituting a distinct biological subtype, whereas severe depression is linked to TNF-alpha-driven inflammation. If replicated, this dichotomy could reshape how researchers and clinicians think about the heterogeneity of depression. Instead of treating all patients as having a single illness with variable intensity, biomarker profiles might identify mechanistically distinct subgroups—those whose symptoms are tied to intestinal barrier dysfunction and endotoxin leakage, and those whose illness is dominated by systemic cytokine activity.

Such a framework has therapeutic implications. A patient subgroup characterized by gut-derived inflammation might respond to interventions targeting the intestinal barrier or the microbiome, ranging from dietary strategies to anti-inflammatory agents, while a TNF-alpha-dominated subgroup might be more plausibly matched to immunomodulatory treatments, some of which are already being explored in treatment-resistant depression. The authors suggest that these biomarkers may aid in distinguishing depression subtypes and informing targeted therapeutic strategies, a vision that aligns with the broader push toward precision psychiatry, in which laboratory measures complement clinical interviews in guiding care.

The study also carries caveats typical of cross-sectional research. Blood samples capture a single moment in time, so the findings cannot establish whether elevated LPS precedes the onset of mild-to-moderate depression or results from it, nor can they track how biomarkers fluctuate as illness waxes and wanes. The sample, drawn from a single region and registered on ClinicalTrials.gov, will need replication in larger and more diverse cohorts before LPS and cytokine panels can be proposed for clinical use. The diagnostic accuracies reported, while statistically robust, remain below the thresholds generally demanded of a standalone screening test, positioning these markers as components of a multi-marker panel rather than definitive diagnostics.

Nevertheless, the work adds momentum to a growing body of evidence linking the gut, the immune system, and the brain in psychiatric illness. By showing that the direction and composition of inflammatory signaling differ systematically with depression severity, the Lithuanian-Cambridge collaboration offers both a practical lead—blood-based markers that track disease subtypes—and a mechanistic hypothesis: that a leaky gut may help fuel a recognizable form of depression, while deeper illness engages a different inflammatory engine. For a disorder that lacks established biological markers, that is a consequential step, and one that future longitudinal and interventional studies will be eager to test.

Subject of Research: Circulating lipopolysaccharide and cytokine levels as severity-dependent biomarkers in major depressive disorder

Article Title: Lipopolysaccharide and cytokine levels differ by disease severity in major depressive disorder

Article References: Milasauskiene, E., Burkauskas, J., Jesmanas, S., Gleizniene, R., Borutaite, V., Raskauskiene, N., Skemiene, K., Adomaitiene, V., Gradauskiene, B., Brown, G. C., & Steibliene, V. (2026). Lipopolysaccharide and cytokine levels differ by disease severity in major depressive disorder. Discover Mental Health. https://doi.org/10.1007/s44192-026-00587-1

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00587-1

Keywords: major depressive disorder, lipopolysaccharide, endotoxin, cytokines, TNF-alpha, interleukin-10, inflammation, gut-derived inflammation, biomarkers, depression severity, immune dysregulation, precision psychiatry